- Home
- AQST vs PRME Comparison
AQST vs PRME Comparison
Compare AQST & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | PRME |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 666.1M |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AQST | PRME |
|---|---|---|
| Price | $3.95 | $3.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $8.83 | $6.42 |
| AVG Volume (30 Days) | ★ 4.8M | 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,430,000.00 | $2,983,000.00 |
| Revenue This Year | N/A | $95.64 |
| Revenue Next Year | $17.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.20 | $1.11 |
| 52 Week High | $7.55 | $6.94 |
Technical Indicators
Market Signals| Indicator | AQST | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 38.39 |
| Support Level | $3.72 | $3.18 |
| Resistance Level | $3.99 | $3.39 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 44.23 | 8.52 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.